Search the RE article base
Contact Information
Twitter
My TweetsUseful Web Sites
Author Archives: Gerald Barnett
Reflections on Shill Reflections on Bayh-Dole, 3: Fake history, sparking innovation, and a pernicious requirement
[I have made revisions and additions and placed the second half of this article in part 4.] We are still reflecting on reflections on Bayh-Dole by “leaders” hoping that you will follow them. More: prior to the Act, the government … Continue reading
Posted in Bayh-Dole, Policy
Tagged Bayh-Dole, leaders, NSF, pernicious plan, Vannevar Bush
Comments Off on Reflections on Shill Reflections on Bayh-Dole, 3: Fake history, sparking innovation, and a pernicious requirement
Reflections on Shill Reflections on Bayh-Dole, 2: Commercialization and certainty
We are working through reflections of Bayh-Dole made by some iron rings in cows’ noses that claim to give milk–er, “industry leaders.” The exercise is useful not merely to mock them for their nonsense–mockery is here salutory and inclusive–but also … Continue reading
Posted in Bayh-Dole, Policy
Tagged Bayh-Dole, certainty, commercialization
Comments Off on Reflections on Shill Reflections on Bayh-Dole, 2: Commercialization and certainty
Reflections on Shill Reflections on Bayh-Dole, 1: Intent and utilization
Rebecca Tapscott has posted an article at IP Watchdog, “Industry Leaders Reflect on Bayh-Dole at 40.” There are lots of problems with this article–and with the “leaders’” “reflections” when it comes to Bayh-Dole. But hey, folks are entitled to mis-remember … Continue reading
Posted in Bayh-Dole, History, Technology Transfer
Tagged 35 USC 200, Bayh-Dole, ineptocrats, intent
Comments Off on Reflections on Shill Reflections on Bayh-Dole, 1: Intent and utilization
University Patent Policy for Effective Technology Transfer, 2: Non-exclusive, voluntary, negotiated practice for effective technology transfer
We will get into the operational details of non-exclusive, voluntary, negotiated university IP management for effective technology transfer. Short answer–everything is navigable and has already been done, even if folks have forgotten how to do it. We can look at … Continue reading
Posted in Policy, Technology Transfer
Tagged crappy, non-exclusive, patent policy, technology transfer
Comments Off on University Patent Policy for Effective Technology Transfer, 2: Non-exclusive, voluntary, negotiated practice for effective technology transfer
University Patent Policy for Effective Technology Transfer, 1: Outline
Universities have never had patent policies centered on technology transfer. Not back when, not now. It should come as no surprise that universities don’t track technology transfer and don’t report their outcomes. What would a university technology transfer IP policy … Continue reading
Posted in Policy, Projects, Technology Transfer
Tagged project, technology transfer
Comments Off on University Patent Policy for Effective Technology Transfer, 1: Outline
The Wall Street Journal publishes an editorial against using Bayh-Dole march-in for remdesivir
Sally Pipes has published an op/ed piece at the Wall Street Journal on Bayh-Dole and Gilead, “The Remdesivir Patent Isn’t State Property.” There is so much going on with Pipes’s work. We should take a closer look. First, the title … Continue reading
Posted in Bayh-Dole, high priced medicines, Policy
Tagged Bayh-Dole, ludicrous, march-in, remdesivir
Comments Off on The Wall Street Journal publishes an editorial against using Bayh-Dole march-in for remdesivir
Bayh-Dole’s repeal is more worser Bayh-Dole
I’ve worked this idea before, but I will try again. What happens if Bayh-Dole is repealed? First, things fall back to EO 12591, which stipulates that the heads of federal departments and agencies shall, among other things (1)(b)(4): promote the … Continue reading
AUTM weighs in on march-in for remdesivir
AUTM has issued a statement on march-in with respect to remdesivir. To date, AUTM has never supported march-in. This new statement is no exception. Howard Bremer, an AUTM founder back when AUTM was SUPA, worked on the implementing regulations for … Continue reading
Posted in Bayh-Dole, high priced medicines, Policy
Tagged AUTM, Bayh-Dole, remdesivir
Comments Off on AUTM weighs in on march-in for remdesivir
On Technology Transfer Metrics, 6: What university administrators want most
We are looking at metrics for managing university-based technology transfer and policy. First, we have none. We have disconnected proxies that don’t inform either management or policy. Let’s look at what university administrators care about: money. That’s it. I have … Continue reading
On Technology Transfer Metrics, 5: Metrics relative to mission
Who it is that most wants technology change. Or, more particularly, who is it that we ought to want to make technology change? My bet is that the top of that list is not occupied by patent bureaucrats. It’s not, … Continue reading
Posted in Metrics, Technology Transfer
Tagged bureaucrats, metrics, technology change, technology transfer
Comments Off on On Technology Transfer Metrics, 5: Metrics relative to mission